Ventricular tachycardia exiting at the left ventricular papillary muscle accounts for 33% of exit sites in heart failure patients and is associated with a higher rate of VT recurrence (p=0.03).
Does the presence of a ventricular tachycardia exit site at the left ventricular papillary muscle affect VT recurrence and mortality in heart failure patients with LVEF <35% undergoing catheter ablation?
In heart failure patients with LVEF <35% undergoing VT ablation, a VT exit site at the left ventricular papillary muscle is associated with significantly higher VT recurrence and a trend toward increased 1-year mortality.
Absolute Event Rate: 0% vs 0%
Background and (ii) evaluate the outcomes of catheter ablation, including VT recurrence and mortality. Methods This is a retrospective single-centre study, including patients with LVEF Results A total of 48 patients were included (age 68±11 years; males 93%; LVEF 27±6%; ischaemic cardiomyopathy 56%; non-ischaemic cardiomyopathy 39%; mixed cardiomyopathy 4%). The main findings were: (i) 33% of the VT exit sites were located at LV PM; (ii) 68% patients had LV PM abnormal tissue characteristics on intracardiac echocardiography; however, such characteristics were not indicative of VT exit; (iii) the presence of VT exit in the LV PM was associated with a higher rate of VT recurrence (log-rank p=0.03), and a trend towards higher mortality at 1 year (log-rank p=0.07). Conclusions In patients with LVEF <35%, VT with endocavitary structures as exit sites is not uncommon. Patients with VT exiting at the LV PM have worse clinical outcomes with higher VT recurrence and mortality.
So et al. (Wed,) reported a other. Ventricular tachycardia exiting at the left ventricular papillary muscle accounts for 33% of exit sites in heart failure patients and is associated with a higher rate of VT recurrence (p=0.03).